The use angiogenesis stimulators for the treatment of chronic ischemia of lower extremities.

Abstract

We present the results of treatment of chronic ischemia of the lower extremities (distal form) with angiogenesis stimulators, autologous endothelioblast precursors (CD133+) and gene preparation of vascular endothelial growth factor VEGF165 (angiostimulin). Good clinical effect was attained in all patients, which was confirmed instrumentally 1, 3, and 6 months after administration of the stimulant: transcutaneous oxygen tension on the foot, index of malleolar pressure, and walking duration increased, parameters of microcirculation improved, the number of newly formed collateral arteries increased (angiography findings), quality of life improved (SF 36 questionnaire), and parameters of coagulogram also improved. The maximum positive dynamics was observed by month 3 of the study.

• Authors: L A Bokeriya, V S Arakaelyan, M V Eremeeva, N D Nisnevich, M G Plyushch, D I Kolesnik, O A Demidova
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 144 Issue 1 Pg. 141-6 (Jul 2007) ISSN: 0007-4888 [Print] United States
• PMID: 18256773 (Publication Type: Journal Article)

Chemical References

• AC133 Antigen
• Angiogenesis Inducing Agents
• Antigens, CD
• Glycoproteins
• PROM1 protein, human
• Peptides

Topics

• AC133 Antigen
• Adult
• Aged
• Aged, 80 and over
• Angiogenesis Inducing Agents (therapeutic use)
• Angiography
• Antigens, CD (therapeutic use)
• Cell- and Tissue-Based Therapy (methods)
• Chronic Disease
• Female
• Genetic Therapy (methods)
• Glycoproteins (therapeutic use)
• Humans
• Ischemia (drug therapy)
• Leg (blood supply)
• Male
• Middle Aged
• Peptides (therapeutic use)